Literature DB >> 7319441

[Cerebrospinal fluid passage of therapeutic immunoglobulins of the IgG class in infectious inflammatory disease of the CNS].

I Neu, F Kreuter, M Prosiegel, V Pfaffenrath, W Autenrieth, H Bauer.   

Abstract

Immunoglobulins are often used as an optimizing therapy in cases of infectious diseases of the central nervous system. To clarify the question of whether or not an intravenously administered compound of the IgG class is able to penetrate the cerebrospinal fluid barrier despite its high molecular weight, 12 anti-HBs negative patients received 20 ml each of a beta-Propiolacton treated IgG compound with a high anti-HBs titre (1 : 115 000) used as a marker. Four patients having an inconspicuous fluid condition were consulted for control. Five patients were suffering from slight disturbances and three other patients had severe disorders of the blood-cerebrospinal fluid barrier function resulting from inflammatory diseases of the central nervous systems. Cerebrospinal fluid was produced by way of lumbar puncture resp. drainage for the determination of anti-HBs. Simultaneously, the concentration of antibodies in serum was determined. In all patients having barrier disturbances, anti-HBs was evident in the cerebrospinal fluid, the transfer of intravenously administered immunoglobulins to cerebrospinal fluid increasing in correlation with the degree of the barrier disorder. The therapeutical importance of immunoglobulin therapy in treating infections of the central nervous system is pointed out.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7319441

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  2 in total

Review 1.  Passage of intravenous immunoglobulin and interaction with the CNS.

Authors:  U Wurster; J Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

2.  [Immunoglobulins in the treatment of bacterial meningitis in childhood].

Authors:  R Noack; C Szugs; H Scholz
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.